
|
Urologic Oncology Fellowship Faculty
Dr.
Adam S. Kibel, professor of urology and director of urologic oncology
in the Division of Urology, serves as program director of the Urologic Oncology
Fellowship. In addition, Dr. Kibel is a member of the Siteman Cancer Center
and a professor in the Department of Genetics. He has a busy clinical practice
focused on prostate, bladder, kidney and testis cancer, employing both minimally
invasive and open approaches to all tumor types. Dr. Kibel also runs a productive
laboratory that focuses on the genetic determinants of urologic cancer.
He has mentored fellows, post-doctoral PhD fellows, residents and medical
students both clinically and in the laboratory. Fellows work closely with
Dr. Kibel both in the clinical arena and in implementing clinical and laboratory
research projects.
Dr. Robert (Sherb) Figenshau,
professor in the Division of Urology and director of Minimally Invasive Urology,
assists in directing the minimally invasive surgical experience for fellows.
He has a busy clinical practice focused on minimally invasive approaches to
urologic oncology. In addition, he directs a large animal laboratory where
fellows can investigate novel minimally invasive treatment approaches to urologic
malignancies. Fellows work with Dr. Figenshau both clinically and in the laboratory
Dr. Gerald L. Andriole, professor
and chief of the Division of Urologic Surgery, is a central member of the
fellowship experience. Dr. Andriole is a member of the Siteman Cancer Center
and has leadership roles in many national and international prostate research
projects. Dr. Andriole serves as chairman of the Prostate Committee of the
NCI-directed Prostate, Lung, Colorectal and Ovarian [PLCO] Cancer Screening
Trial. He has a busy oncology practice focusing on the treatment of prostate
cancer. Fellows work with Dr. Andriole in the operating room and collaborate
on research projects during their fellowship.
Dr.
Robert L. Grubb, an assistant professor in the Division of Urology and
a member of the Siteman Cancer Center, serves as assistant program director
of the fellowship. He also has a busy clinical practice focused on urologic
oncology including both minimally invasive and open approaches to all tumor
types. He is actively involved in the Prostate, Lung, Colorectal and Ovarian
(PLCO) Cancer Screening Trial. Additionally, his laboratory is focusing
on using MRI to image localized prostate cancer and markers of chemoresponsiveness
in bladder cancer. Fellows work with Dr. Grubb in the clinical arena and
have the opportunity to work with him on research projects.
Dr.
Sam Bhayani, as assistant profesor in the Division of Urology, is director
of the Minimally Invasive Laboratory and co-director of the Robotic Program.
He specializes in the treatment of prostate cancers and kidney cancers,
tumors and masses in a minimally invasive fashion (laparoscopic and robotic).
Dr. Jeff Arbeit, professor
and a member of the Siteman Cancer, is the scientific director of the Division
of Urologic Surgery. Dr. Arbeit is an expert in mouse models of cancer and
cancer genetics. His lab currently is focused on developing mouse models of
prostate cancer and understanding the role of mTOR as a potential target for
prostate cancer treatment. Fellows have the opportunity to work in Dr. Arbeit’s
lab; however, he will provide basic science mentorship for the fellows whether
they work in his laboratory or not.
Dr. Jeff
Michalski, professor of radiation oncology, is an integral part of the
fellow’s experience. Dr. Michalski’s practice focuses on the treatment
of urologic cancers, primarily prostate cancer, but also on the bladder and
testis. He is a leader in the field of urologic oncology having been the primary
investigator for multiple Radiation Therapy Oncology Group (RTOG) trials investigating
high-dose external beam irradiation (EBRT) and brachytherapy. Fellows rotate
half a day per week with Dr. Michalski during their clinical year. They focus
on both treatment (e.g., brachytherapy, EBRT) and patient selection (e.g.,
neoadjuvant hormone ablation, bladder preservation protocols).
Dr. Joel
Picus, associate professor of medicine in the Division of Medical Oncology,
also works with fellows. His practice focuses on the treatment of urologic
cancers, including malignancies of the prostate, bladder, kidney and testis.
He is a leader in the field of urologic oncology who has been the primary
investigator for multiple institutional and national clinical trials. Fellows
rotate half a day per week with Dr. Picus during their clinical year to become
familiar with patient selection for chemotherapy and clinical chemotherapy
trial design.
Washington University physicians are the medical staff of Barnes-Jewish Hospital and St. Louis Children's Hospital
|